Gra-CRC-miRTar: The pre-trained nucleotide-to-graph neural networks to identify potential miRNA targets in colorectal

Rui Yin1, Hongru Zhao1, Lu Li2

  • 1Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, FL, USA.

Insights

We developed Gra-CRC-miRTar, a novel deep learning framework, to accurately identify microRNA (miRNA) targets in colorectal cancer (CRC). This tool aids in understanding cancer mechanisms and developing new therapeutics.

Area of Science:

  • Bioinformatics
  • Computational Biology
  • Oncology

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer death globally.
  • MicroRNAs (miRNAs) play crucial roles as oncogenes or tumor suppressors in CRC development.
  • Identifying miRNA-mRNA interactions is vital for therapeutic advancements in CRC.

Purpose of the Study:

  • To develop a novel computational framework, Gra-CRC-miRTar, for identifying potential miRNA targets in colorectal cancer.
  • To leverage deep learning and graph neural networks for enhanced prediction accuracy.
  • To provide a tool for uncovering miRNA-mediated regulatory mechanisms in CRC.

Main Methods:

  • Constructed pre-trained nucleotide-to-graph models encoding RNA sequences as de Bruijn graphs.
  • Utilized graph neural networks to learn latent representations of RNA sequences.
  • Employed a Multilayer Perceptron (MLP) for predicting miRNA-target interactions.

Main Results:

  • Gra-CRC-miRTar demonstrated superior performance compared to existing deep learning algorithms and predictors.
  • The framework successfully identified 172 experimentally validated functional miRNA-mRNA interactions in CRC.
  • Achieved high accuracy in predicting potential miRNA targets crucial for CRC.

Conclusions:

  • Gra-CRC-miRTar offers an accurate and efficient method for identifying miRNA targets in colorectal cancer.
  • The framework can be extended to investigate miRNA targets in other cancer types.
  • This work facilitates the development of novel miRNA-based therapeutic strategies for malignancies.